These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 23183050)
1. 100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco. Canonica GW; Baena-Cagnani CE; Compalati E; Bohle B; Bonini S; Bousquet J; Cox L; Fink-Wagner AH; González Díaz S; Jacobsen L; Passalacqua G; Pawankar R; Vieths S; Yusuf O; Zuberbier T Int Arch Allergy Immunol; 2013; 160(4):346-9. PubMed ID: 23183050 [TBL] [Abstract][Full Text] [Related]
3. A review of allergy and allergen specific immunotherapy. Bidad K; Nicknam MH; Farid R Iran J Allergy Asthma Immunol; 2011 Mar; 10(1):1-9. PubMed ID: 21358009 [TBL] [Abstract][Full Text] [Related]
4. History of immunotherapy: the first 100 years. Fitzhugh DJ; Lockey RF Immunol Allergy Clin North Am; 2011 May; 31(2):149-57, vii. PubMed ID: 21530811 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy: The meta-analyses. What have we Learned? Calderón MA; Boyle RJ; Penagos M; Sheikh A Immunol Allergy Clin North Am; 2011 May; 31(2):159-73, vii. PubMed ID: 21530812 [TBL] [Abstract][Full Text] [Related]
13. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Focke M; Swoboda I; Marth K; Valenta R Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812 [TBL] [Abstract][Full Text] [Related]
14. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280 [TBL] [Abstract][Full Text] [Related]
15. [GUIDE TO ALLERGEN IMMUNOTHERAPY FOR MITE ALLERGY]. Gotoh M Arerugi; 2017; 66(6):788-791. PubMed ID: 28701643 [No Abstract] [Full Text] [Related]
16. What should drive the choice of allergen for immunotherapy in polysensitized patients? Ciprandi G; Incorvaia C; Puccinelli P; Dell'Albani I; Frati F Ann Allergy Asthma Immunol; 2012 Aug; 109(2):148-9. PubMed ID: 22840259 [No Abstract] [Full Text] [Related]
17. Mechanisms of subcutaneous allergen immunotherapy. Soyer OU; Akdis M; Akdis CA Immunol Allergy Clin North Am; 2011 May; 31(2):175-90, vii-viii. PubMed ID: 21530813 [TBL] [Abstract][Full Text] [Related]
18. T regulatory cells in allergen-specific immunotherapy. Verhagen J; Taylor A; Blaser K; Akdis M; Akdis CA Int Rev Immunol; 2005; 24(5-6):533-48. PubMed ID: 16318994 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Rossi RE; Monasterolo G Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445 [TBL] [Abstract][Full Text] [Related]
20. Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes. Cox L; Esch RE; Corbett M; Hankin C; Nelson M; Plunkett G Ann Allergy Asthma Immunol; 2011 Oct; 107(4):289-99; quiz 300. PubMed ID: 21962088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]